Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)

NCT02292225 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT02292225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02292225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)
Lead sponsor
SecuraBio
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2015
Completion date
November 30, 2016
Enrollment
3 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic, lymphoma, small lymphocytic